AR074330A1 - Nuevo procedimiento para la preparacion de granulos de principios activos y granulos asi obtenidos - Google Patents
Nuevo procedimiento para la preparacion de granulos de principios activos y granulos asi obtenidosInfo
- Publication number
- AR074330A1 AR074330A1 ARP090104388A ARP090104388A AR074330A1 AR 074330 A1 AR074330 A1 AR 074330A1 AR P090104388 A ARP090104388 A AR P090104388A AR P090104388 A ARP090104388 A AR P090104388A AR 074330 A1 AR074330 A1 AR 074330A1
- Authority
- AR
- Argentina
- Prior art keywords
- granulate
- granules
- active principles
- stage
- polyols
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Fertilizers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Glanulating (AREA)
- Seasonings (AREA)
- Fodder In General (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente se refiere a un procedimiento de preparación de un granulado de, al menos, dos principios activos, que comprende una etapa de aplicación por polvificado de dichos principios activos sobre un soporte particular sólido, y dichos principios activos no son extractos de plantas. Reivindicación 2: Procedimiento de acuerdo con la reivindicación 1, caracterizado porque la etapa de polvificado comprende la pulverización de una solución acuosa, alcohólica o hidroalcohólica de un aglutinante. Reivindicación 3: Procedimiento de acuerdo con la reivindicación 1 o 2, caracterizado porque comprende, después de la etapa de polvificado, una etapa de recubrimiento del granulado, en especial, depositando por peliculado el agente de recubrimiento en forma de película sobre el granulado, seguida dado el caso, de una etapa de mezclado con un lubricante y/o un aromatizante y/o un edulcorante y/o un colorante. Reivindicación 4: Procedimiento de acuerdo con cualquiera de las reivindicaciones 1 a 3, en el cual el soporte se elige en el grupo constituido por polioles tales como manitol, sorbitol, maltitol o xilitol, lactosa, fosfato dicálcico, carbonatos, tales como carbonato de calcio, de potasio, de magnesio o de sodio, gluconatos, silicatos, cristales de azúcar, sacarosa y derivados de sílice. Reivindicación 5: Procedimiento de acuerdo con cualquiera de las reivindicaciones 2 a 4, en el cual el aglutinante se elige en el grupo constituido por almidón, sacarosa, goma arábiga, polivinilpirrolidona, hidroxipropilmetilcelulosa, goma laca, hidrocipropilcelulosa, celulosa, polioles, alginatos, glicéridos poliglicolizados o macrogolglicéridos, en especial, macrogolglicéridos de estearoílo. Reivindicación 8: Granulado de acuerdo con la reivindicación 7, caracterizado porque el núcleo sólido no es un núcleo neutro.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0857764A FR2938432B1 (fr) | 2008-11-14 | 2008-11-14 | Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus |
Publications (1)
Publication Number | Publication Date |
---|---|
AR074330A1 true AR074330A1 (es) | 2011-01-05 |
Family
ID=40348849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090104388A AR074330A1 (es) | 2008-11-14 | 2009-11-13 | Nuevo procedimiento para la preparacion de granulos de principios activos y granulos asi obtenidos |
Country Status (25)
Country | Link |
---|---|
US (1) | US20110280945A1 (es) |
EP (1) | EP2349226A1 (es) |
JP (1) | JP5608681B2 (es) |
KR (1) | KR101585705B1 (es) |
CN (1) | CN102223879A (es) |
AR (1) | AR074330A1 (es) |
AU (1) | AU2009315449B2 (es) |
BR (1) | BRPI0916019A2 (es) |
CA (1) | CA2743753A1 (es) |
CL (1) | CL2011001115A1 (es) |
CO (1) | CO6382108A2 (es) |
CU (1) | CU20110107A7 (es) |
EA (1) | EA201100757A1 (es) |
FR (1) | FR2938432B1 (es) |
IL (1) | IL212850A0 (es) |
MA (1) | MA32789B1 (es) |
MX (1) | MX2011005072A (es) |
NZ (1) | NZ592857A (es) |
PE (1) | PE20110945A1 (es) |
SG (1) | SG195651A1 (es) |
TN (1) | TN2011000235A1 (es) |
TW (1) | TWI522113B (es) |
UA (1) | UA103781C2 (es) |
WO (1) | WO2010055268A1 (es) |
ZA (1) | ZA201103543B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2971422B1 (fr) * | 2011-02-11 | 2016-05-20 | Debregeas Et Associes Pharma | Granules d'acide gamma-hydroxybutyrique |
US20140127296A1 (en) * | 2012-11-05 | 2014-05-08 | Kenneth John Tibbs | Pharmaceutical preparation and method for treatment of diabetes |
US9241956B2 (en) * | 2012-11-05 | 2016-01-26 | Kenneth John Tibbs | Pharmaceutical preparation and method for treatment of diabetes |
US11058635B1 (en) * | 2020-10-15 | 2021-07-13 | King Abdulaziz University | Oral administration of 5-FU in a gelling nanosuspension for targeted delivery to treat colorectal cancers |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6327424A (ja) * | 1986-07-17 | 1988-02-05 | Shionogi & Co Ltd | 徐放性製剤およびその製造法 |
JP2820829B2 (ja) * | 1991-03-07 | 1998-11-05 | 武田薬品工業株式会社 | 有核散剤およびその製造方法 |
JPH08310969A (ja) * | 1995-05-22 | 1996-11-26 | Lion Corp | 固形薬品組成物及びその製造方法 |
FR2790668B1 (fr) * | 1999-03-12 | 2002-07-26 | D B F | Granules contenant une substance vegetale et leur procede de preparation |
WO2000069414A2 (fr) * | 1999-05-17 | 2000-11-23 | D.B.F. | Granules contenant une substance vegetale et leur procede de preparation |
MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
US9247765B2 (en) * | 2004-01-14 | 2016-02-02 | Omniactive Health Technologies Limited | Stable beadlets of lipophilic nutrients |
FR2880541B1 (fr) * | 2005-01-10 | 2008-02-22 | Amalric Veret | Une nouvelle formule de plantes sous forme de micro-granules de xilitol pour renforcer les effets des plantes et leurs proprietes par une meilleure assimilation |
US20060182796A1 (en) * | 2005-02-03 | 2006-08-17 | Abrika Pharmaceuticals, Inc. | Taste masked pharmaceutical compositions |
CA2661683C (en) * | 2006-08-31 | 2015-11-24 | Eurand, Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
CN101611099B (zh) * | 2007-02-14 | 2013-01-02 | 大日精化工业株式会社 | 有机颜料的分散剂及其使用 |
US20090004281A1 (en) * | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
-
2008
- 2008-11-14 FR FR0857764A patent/FR2938432B1/fr not_active Expired - Fee Related
-
2009
- 2009-11-13 CA CA2743753A patent/CA2743753A1/fr not_active Abandoned
- 2009-11-13 WO PCT/FR2009/052180 patent/WO2010055268A1/fr active Application Filing
- 2009-11-13 MX MX2011005072A patent/MX2011005072A/es active IP Right Grant
- 2009-11-13 US US13/129,028 patent/US20110280945A1/en not_active Abandoned
- 2009-11-13 JP JP2011543800A patent/JP5608681B2/ja not_active Expired - Fee Related
- 2009-11-13 UA UAA201105988A patent/UA103781C2/uk unknown
- 2009-11-13 BR BRPI0916019A patent/BRPI0916019A2/pt not_active Application Discontinuation
- 2009-11-13 KR KR1020117013588A patent/KR101585705B1/ko active IP Right Grant
- 2009-11-13 CN CN2009801457596A patent/CN102223879A/zh active Pending
- 2009-11-13 SG SG2013082482A patent/SG195651A1/en unknown
- 2009-11-13 NZ NZ592857A patent/NZ592857A/xx not_active IP Right Cessation
- 2009-11-13 EA EA201100757A patent/EA201100757A1/ru unknown
- 2009-11-13 EP EP09768187A patent/EP2349226A1/fr not_active Withdrawn
- 2009-11-13 AR ARP090104388A patent/AR074330A1/es unknown
- 2009-11-13 PE PE2011001032A patent/PE20110945A1/es not_active Application Discontinuation
- 2009-11-13 AU AU2009315449A patent/AU2009315449B2/en not_active Ceased
- 2009-11-16 TW TW098138860A patent/TWI522113B/zh not_active IP Right Cessation
-
2011
- 2011-05-12 IL IL212850A patent/IL212850A0/en unknown
- 2011-05-12 TN TN2011000235A patent/TN2011000235A1/fr unknown
- 2011-05-13 CU CU20110107A patent/CU20110107A7/es unknown
- 2011-05-13 MA MA33837A patent/MA32789B1/fr unknown
- 2011-05-13 CO CO11059023A patent/CO6382108A2/es not_active Application Discontinuation
- 2011-05-13 ZA ZA2011/03543A patent/ZA201103543B/en unknown
- 2011-05-13 CL CL2011001115A patent/CL2011001115A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010055268A1 (fr) | 2010-05-20 |
JP5608681B2 (ja) | 2014-10-15 |
IL212850A0 (en) | 2011-07-31 |
AU2009315449A1 (en) | 2010-05-20 |
MA32789B1 (fr) | 2011-11-01 |
JP2012508786A (ja) | 2012-04-12 |
US20110280945A1 (en) | 2011-11-17 |
NZ592857A (en) | 2013-07-26 |
TWI522113B (zh) | 2016-02-21 |
BRPI0916019A2 (pt) | 2015-11-10 |
MX2011005072A (es) | 2011-10-03 |
TN2011000235A1 (fr) | 2012-12-17 |
ZA201103543B (en) | 2012-01-25 |
CA2743753A1 (fr) | 2010-05-20 |
FR2938432B1 (fr) | 2011-05-20 |
AU2009315449B2 (en) | 2015-03-26 |
EP2349226A1 (fr) | 2011-08-03 |
CO6382108A2 (es) | 2012-02-15 |
CL2011001115A1 (es) | 2011-11-11 |
TW201029667A (en) | 2010-08-16 |
UA103781C2 (uk) | 2013-11-25 |
KR101585705B1 (ko) | 2016-01-15 |
SG195651A1 (en) | 2013-12-30 |
KR20110095888A (ko) | 2011-08-25 |
FR2938432A1 (fr) | 2010-05-21 |
PE20110945A1 (es) | 2012-02-01 |
EA201100757A1 (ru) | 2011-12-30 |
CN102223879A (zh) | 2011-10-19 |
CU20110107A7 (es) | 2012-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191911T1 (hr) | Granule gama-hidroksibutirične kiseline | |
EP1932530A4 (en) | MEANS FOR IMPROVING COLLAGEN PRODUCTION AND ITS USE | |
WO2010025931A3 (en) | Pharmaceutical combination of 3- (3-dimethylamino-1-ethyl-2 -methyl-propyl) - phenol and an antiepileptic | |
SG190448A1 (en) | Rapidly dispersing granules, orally disintegrating tablets and methods | |
IL195732A (en) | Pharmaceutical compounds containing passoterodine, their use and method for their preparation | |
AR074330A1 (es) | Nuevo procedimiento para la preparacion de granulos de principios activos y granulos asi obtenidos | |
AR047993A1 (es) | Composicion farmaceutica que comprende pimobendano | |
BRPI0609424B8 (pt) | composto inibidor da dipeptidil peptidase-iv e composição farmacêutica compreendendo dito composto como um agente ativo | |
CL2013002505A1 (es) | Composicion farmaceutica oral solida que comprende a) un nucleo de liberacion prolongada que contiene metformina, b) un recubrimiento sellador opcional, y c) un recubrimiento externo de liberacion inmediata que comprende a un agente activo, tal como un inhibidor de dpp-4 o de sglt-2; uso para tratar diabetes mellitus tipo 2. | |
CL2011001853A1 (es) | Uso de una combinacion farmaceutica que comprende linagliptina y un segundo agente antidiabetico seleccionado entre biguanidas, tiazolidindionas, sulfonilureas, glinidas, entre otros, y, opcionalmente, un tercer agente antidiabetico, para tratar diabetes mellitus tipo 2 y complicaciones de la diabetes, entre otras. | |
WO2006011159A3 (en) | Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability | |
BR112012000492A2 (pt) | composição detergente moderadamente alcalina, com baixos teores de coadjuvantes que compreende ácido fitalimido peroxicaproico para tratamento de tecido sólido | |
BRPI0614545B8 (pt) | composição farmacêutica de liberação controlada, seu processo de produção, forma de dosagem oral com revestimento entérico de pacreatina e uso da mesma | |
BRPI0924136B8 (pt) | composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma | |
MX2010004195A (es) | Trans-clomifeno para el sindrome metabolico. | |
WO2010132765A3 (en) | Antibacterial aminoglycoside analogs | |
WO2010132757A3 (en) | Antibacterial aminoglycoside analogs | |
WO2010043408A3 (de) | Mikroverkapseltes fesoterodin | |
BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
WO2008106979A3 (en) | Pharmaceutical compositions comprising flavonoids and xylitol | |
WO2010062122A3 (ko) | 동맥경화 예방 또는 치료용 조성물 | |
WO2008005560A3 (en) | Prevention of thrombotic disorders with active vitamin d compounds | |
WO2010006904A3 (en) | Crystalline forms of rabeprazole sodium | |
WO2009049648A3 (en) | Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof | |
WO2007080525A3 (en) | Herbal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |